Suicide genes for cancer therapy

Molecular Aspects of Medicine

Volumn 28, Issue 1, 2007, Pages 4-41

  Portsmouth, Daniel ^a,b   Hlavaty, Juraj ^a   Renner, Matthias ^c  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b INSTITUTE FOR MICROELECTRONICS   (Austria)

^c Austrianova Biomanufacturing Company   (Austria)

Author keywords

Bystander effect; Carboxypeptidase G2; Cytochrome P450; Cytosine deaminase; Gene directed enzyme prodrug therapy; Gene therapy; Nitroreductase; Purine nucleoside phosphorylase; Suicide gene; Thymidine kinase

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 6 MERCAPTOPURINE DERIVATIVE; 6 THIOXANTHINE; ACICLOVIR; BETA GLUCURONIDASE; CARBOXYLESTERASE; CARBOXYPEPTIDASE A; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450; CYTOSINE DEAMINASE; DEOXYCYTIDINE KINASE; DOXORUBICIN; ENZYME; FLUCYTOSINE; FLUDARABINE; GANCICLOVIR; GEMCITABINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IFOSFAMIDE; NITROREDUCTASE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; THYMINE ARABINOSIDE; TIOGUANINE; UNINDEXED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER THERAPY; ENZYME THERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; IMMUNE SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; SUICIDE GENE;

ANIMALS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; NEOPLASMS;

ANIMALIA;

EID: 33847319117     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2006.12.001     Document Type: Review

References (300)

1. Adachi Y., Tamiya T., Ichikawa T., Terada K., Ono Y., Matsumoto K., Furuta T., Hamada H., and Ohmoto T. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum. Gene Ther. 11 1 (2000) 77-89
2. Agarwal S., Nikolai B., Yamaguchi T., Lech P., and Somia N.V. Construction and use of retroviral vectors encoding the toxic gene barnase. Mol. Ther. 14 4 (2006) 555-563
3. Andersen L., Kilstrup M., and Neuhard J. Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coli K 12. Involvement of the glnLG and purR genes in the regulation of codA expression. Arch. Microbiol. 152 2 (1989) 115-118
4. Anderson L.M., Krotz S., Weitzman S.A., and Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther. 7 6 (2000) 845-852
5. Anlezark G.M., Melton R.G., Sherwood R.F., Coles B., Friedlos F., and Knox R.J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44 12 (1992) 2289-2295
6. Austin E.A., and Huber B.E. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43 3 (1993) 380-387
7. Ayala G., Satoh T., Li R., Shalev M., Gdor Y., Aguilar-Cordova E., Frolov A., Wheeler T.M., Miles B.J., Rauen K., Teh B.S., Butler E.B., Thompson T.C., and Kadmon D. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol. Ther. 13 4 (2006) 716-728
8. Barton K.N., Paielli D., Zhang Y., Koul S., Brown S.L., Lu M., Seely J., Kim J.H., and Freytag S.O. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 13 2 (2006) 347-356
9. Bauerschmitz G.J., Guse K., Kanerva A., Menzel A., Herrmann I., Desmond R.A., Yamamoto M., Nettelbeck D.M., Hakkarainen T., Dall P., Curiel D.T., and Hemminki A. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol. Ther. 14 2 (2006) 164-174
10. Beltinger C., Fulda S., Walczak H., and Debatin K.M. TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. Cancer Gene Ther. 9 4 (2002) 372-381
11. Bennett E.M., Anand R., Allan P.W., Hassan A.E., Hong J.S., Levasseur D.N., McPherson D.T., Parker W.B., Secrist III J.A., Sorscher E.J., Townes T.M., Waud W.R., and Ealick S.E. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem. Biol. 10 12 (2003) 1173-1181
12. Bharara S., Sorscher E.J., Gillespie G.Y., Lindsey J.R., Hong J.S., Curlee K.V., Allan P.W., Gadi V.K., Alexander S.A., Secrist III J.A., Parker W.B., and Waud W.R. Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. Hum. Gene Ther. 16 3 (2005) 339-347
13. Black M.E., Newcomb T.G., Wilson H.M., and Loeb L.A. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA 93 8 (1996) 3525-3529
14. Black M.E., Kokoris M.S., and Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 61 7 (2001) 3022-3026
15. Blakey D.C., Burke P.J., Davies D.H., Dowell R.I., East S.J., Eckersley K.P., Fitton J.E., McDaid J., Melton R.G., Niculescu-Duvaz I.A., Pinder P.E., Sharma S.K., Wright A.F., and Springer C.J. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts. Cancer Res. 56 14 (1996) 3287-3292
16. Boucher P.D., and Shewach D.S. In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine. Mol. Ther. 12 6 (2005) 1064-1071
17. Boucher P.D., Ostruszka L.J., Murphy P.J., and Shewach D.S. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 9 15 (2002) 1023-1030
18. Braybrooke J.P., Slade A., Deplanque G., Harrop R., Madhusudan S., Forster M.D., Gibson R., Makris A., Talbot D.C., Steiner J., White L., Kan O., Naylor S., Carroll M.W., Kingsman S.M., and Harris A.L. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin. Cancer Res. 11 4 (2005) 1512-1520
19. Bridgewater J.A., Springer C.J., Knox R.J., Minton N.P., Michael N.P., and Collins M.K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A 13-14 (1995) 2362-2370
20. Bridgewater J.A., Knox R.J., Pitts J.D., Collins M.K., and Springer C.J. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 8 6 (1997) 709-717
21. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 7 (2000) 1878-1886
22. Bunting K.D., and Townsend A.J. De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. J. Biol. Chem. 271 20 (1996) 11884-11890
23. Bunting K.D., and Townsend A.J. Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J. Biol. Chem. 271 20 (1996) 11891-11896
24. Bzowska A., Kulikowska E., and Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol. Ther. 88 3 (2000) 349-425
25. Cao D., and Pizzorno G. Uridine phosphorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc) 40 5 (2004) 431-443
26. Cao X., Huang X., Ju D.W., Zhang W., Hamada H., and Wang J. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Gene Ther. 7 2 (2000) 177-186
27. Cao L., Si J., Wang W., Zhao X., Yuan X., Zhu H., Wu X., Zhu J., and Shen G. Intracellular localization and sustained prodrug cell killing activity of TAT-HSVTK fusion protein in hepatocellular carcinoma cells. Mol. Cells 21 1 (2006) 104-111
28. Carrio M., Mazo A., Lopez-Iglesias C., Estivill X., and Fillat C. Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: implications for gene therapy. Int. J. Cancer 94 1 (2001) 81-88
29. Chabner B.A., and Roberts Jr. T.G. Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer 5 1 (2005) 65-72
30. Chang T.K., Weber G.F., Crespi C.L., and Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53 23 (1993) 5629-5637
31. Chase M., Chung R.Y., and Chiocca E.A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16 5 (1998) 444-448
32. Chatelut E., Delord J.P., and Canal P. Toxicity patterns of cytotoxic drugs. Invest. New Drugs 21 2 (2003) 141-148
33. Chen L., and Waxman D.J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55 3 (1995) 581-589
34. Chen L., and Waxman D.J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des. 8 15 (2002) 1405-1416
35. Chen L., Waxman D.J., Chen D., and Kufe D.W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56 6 (1996) 1331-1340
36. Chen L., Yu L.J., and Waxman D.J. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 57 21 (1997) 4830-4837
37. Chen S.H., Pearson A., and Coen D.M. Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment. J. Virol. 78 1 (2004) 520-523
38. Chevez-Barrios P., Chintagumpala M., Mieler W., Paysse E., Boniuk M., Kozinetz C., Hurwitz M.Y., and Hurwitz R.L. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J. Clin. Oncol. 23 31 (2005) 7927-7935
39. Chiocca E.A., and Waxman D.J. Cytochrome p450-based gene therapies for cancer. Methods Mol. Med. 90 (2004) 203-222
40. Chung-Faye G., Palmer D., Anderson D., Clark J., Downes M., Baddeley J., Hussain S., Murray P.I., Searle P., Seymour L., Harris P.A., Ferry D., and Kerr D.J. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 7 9 (2001) 2662-2668
41. Chung-Faye G.A., Chen M.J., Green N.K., Burton A., Anderson D., Mautner V., Searle P.F., and Kerr D.J. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 8 20 (2001) 1547-1554
42. Clarke L., and Waxman D.J. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 49 9 (1989) 2344-2350
43. Conrad C., Miller C.R., Ji Y., Gomez-Manzano C., Bharara S., McMurray J.S., Lang F.F., Wong F., Sawaya R., Yung W.K., and Fueyo J. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther. 12 3 (2005) 284-294
44. Consalvo M., Mullen C.A., Modesti A., Musiani P., Allione A., Cavallo F., Giovarelli M., and Forni G. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol. 154 10 (1995) 5302-5312
45. Cortes M.L., de Felipe P., Martin V., Hughes M.A., and Izquierdo M. Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther. 5 11 (1998) 1499-1507
46. Cowen R.L., Williams J.C., Emery S., Blakey D., Darling J.L., Lowenstein P.R., and Castro M.G. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: high-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cancer Gene Ther. 9 11 (2002) 897-907
47. Cowen R.L., Patterson A.V., Telfer B.A., Airley R.E., Hobbs S., Phillips R.M., Jaffar M., Stratford I.J., and Williams K.J. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Mol. Cancer Ther. 2 9 (2003) 901-909
48. Cowen R.L., Williams K.J., Chinje E.C., Jaffar M., Sheppard F.C., Telfer B.A., Wind N.S., and Stratford I.J. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res. 64 4 (2004) 1396-1402
49. Cui W., Gusterson B., and Clark A.J. Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Ther. 6 5 (1999) 764-770
50. Dachs G.U., Tupper J., and Tozer G.M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer. Drugs 16 4 (2005) 349-359
51. Dalba C., Klatzmann D., Logg C.R., and Kasahara N. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr. Gene Ther. 5 6 (2005) 655-667
52. Danielsen S., Kilstrup M., Barilla K., Jochimsen B., and Neuhard J. Characterization of the Escherichia coli codBA operon encoding cytosine permease and cytosine deaminase. Mol. Microbiol. 6 10 (1992) 1335-1344
53. Danks M.K., and Potter P.M. Enzyme-prodrug systems: carboxylesterase/CPT-11. Methods Mol. Med. 90 (2004) 247-262
54. Davies L.C., Friedlos F., Hedley D., Martin J., Ogilvie L.M., Scanlon I.J., and Springer C.J. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. J. Med. Chem. 48 16 (2005) 5321-5328
55. Degreve B., Andrei G., Izquierdo M., Piette J., Morin K., Knaus E.E., Wiebe L.I., Basrah I., Walker R.T., De Clercq E., and Balzarini J. Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer. Gene Ther. 4 10 (1997) 1107-1114
56. Denny W.A. Nitroreductase-based GDEPT. Curr. Pharm. Des. 8 15 (2002) 1349-1361
57. Dilber M.S., Abedi M.R., Christensson B., Bjorkstrand B., Kidder G.M., Naus C.C., Gahrton G., and Smith C.I. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 57 8 (1997) 1523-1528
58. Dilber M.S., Phelan A., Aints A., Mohamed A.J., Elliott G., Smith C.I., and O'Hare P. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther. 6 1 (1999) 12-21
59. Ding S., Yao D., Burchell B., Wolf C.R., and Friedberg T. High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation. Arch. Biochem. Biophys. 348 2 (1997) 403-410
60. Ding S., Yao D., Deeni Y.Y., Burchell B., Wolf C.R., and Friedberg T. Human NADPH-P450 oxidoreductase modulates the level of cytochrome P450 CYP2D6 holoprotein via haem oxygenase-dependent and -independent pathways. Biochem. J. 356 Pt 2 (2001) 613-619
61. Djeha A.H., Hulme A., Dexter M.T., Mountain A., Young L.S., Searle P.F., Kerr D.J., and Wrighton C.J. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther. 7 5 (2000) 721-731
62. Dong J.Y., and Woraratanadharm J. Gene therapy vector design strategies for the treatment of cancer. Future Oncol. 1 3 (2005) 361-373
63. Drabek D., Guy J., Craig R., and Grosveld F. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 4 2 (1997) 93-100
64. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., and Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. USA 74 12 (1977) 5716-5720
65. Elliott G., and O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88 2 (1997) 223-233
66. Erbs P., Exinger F., and Jund R. Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans. Curr. Genet. 31 1 (1997) 1-6
67. Erbs P., Regulier E., Kintz J., Leroy P., Poitevin Y., Exinger F., Jund R., and Mehtali M. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 60 14 (2000) 3813-3822
68. Farquhar D., Pan B.F., Sakurai M., Ghosh A., Mullen C.A., and Nelson J.A. Suicide gene therapy using E. coli beta-galactosidase. Cancer Chemother. Pharmacol. 50 1 (2002) 65-70
69. Fick J., Barker II F.G., Dazin P., Westphale E.M., Beyer E.C., and Israel M.A. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA 92 24 (1995) 11071-11075
70. Fillat C., Carrio M., Cascante A., and Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr. Gene Ther. 3 1 (2003) 13-26
71. Findlay V.J., Townsend D.M., Saavedra J.E., Buzard G.S., Citro M.L., Keefer L.K., Ji X., and Tew K.D. Tumor cell responses to a novel glutathione-S-transferase-activated nitric oxide-releasing prodrug. Mol. Pharmacol. 65 5 (2004) 1070-1079
72. Flader C., Liu J., and Borch R.F. Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase. J. Med. Chem. 43 16 (2000) 3157-3167
73. Fleming R.A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17 5 Pt 2 (1997) 146S-154S
74. Floeth F.W., Shand N., Bojar H., Prisack H.B., Felsberg J., Neuen-Jacob E., Aulich A., Burger K.J., Bock W.J., and Weber F. Local inflammation and devascularization-in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther. 8 11 (2001) 843-851
75. Fonseca M.J., Storm G., Hennink W.E., Gerritsen W.R., and Haisma H.J. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy. J. Gene Med. 1 6 (1999) 407-414
76. Frank S., Steffens S., Fischer U., Tlolko A., Rainov N.G., and Kramm C.M. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy. Cancer Gene Ther. 9 2 (2002) 178-188
77. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L., and Abraham G.N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53 21 (1993) 5274-5283
78. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., Nafziger D., Pegg J., Paielli D., Brown S., Barton K., Lu M., Aguilar-Cordova E., and Kim J.H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62 17 (2002) 4968-4976
79. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., DePeralta-Venturina M., Xia X., Brown S., Lu M., and Kim J.H. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63 21 (2003) 7497-7506
80. Friedlos F., Quinn J., Knox R.J., and Roberts J.J. The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink. Biochem. Pharmacol. 43 6 (1992) 1249-1254
81. Friedlos F., Denny W.A., Palmer B.D., and Springer C.J. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J. Med. Chem. 40 8 (1997) 1270-1275
82. Friedlos F., Court S., Ford M., Denny W.A., and Springer C. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther. 5 1 (1998) 105-112
83. Friedlos F., Davies L., Scanlon I., Ogilvie L.M., Martin J., Stribbling S.M., Spooner R.A., Niculescu-Duvaz I., Marais R., and Springer C.J. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res. 62 6 (2002) 1724-1729
84. Fuerer C., and Iggo R. 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther. 11 2 (2004) 142-151
85. Fujimori M. Genetically engineered bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients. Breast Cancer 13 1 (2006) 27-31
86. Fujita T., Teh B.S., Timme T.L., Mai W.Y., Satoh T., Kusaka N., Naruishi K., Fattah E.A., Aguilar-Cordova E., Butler E.B., and Thompson T.C. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 65 1 (2006) 84-90
87. Fulci G., Breymann L., Gianni D., Kurozomi K., Rhee S.S., Yu J., Kaur B., Louis D.N., Weissleder R., Caligiuri M.A., and Chiocca E.A. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. USA 103 34 (2006) 12873-12878
88. Gadi V.K., Alexander S.D., Kudlow J.E., Allan P., Parker W.B., and Sorscher E.J. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther. 7 20 (2000) 1738-1743
89. Gadi V.K., Alexander S.D., Waud W.R., Allan P.W., Parker W.B., and Sorscher E.J. A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J. Pharmacol. Exp. Ther. 304 3 (2003) 1280-1284
90. Gagandeep S., Brew R., Green B., Christmas S.E., Klatzmann D., Poston G.J., and Kinsella A.R. Prodrug-activated gene therapy: involvement of an immunological component in the bystander effect. Cancer Gene Ther. 3 2 (1996) 83-88
91. Gentry B.G., Boucher P.D., and Shewach D.S. Hydroxyurea induces bystander cytotoxicity in cocultures of herpes simplex virus thymidine kinase-expressing and nonexpressing HeLa cells incubated with ganciclovir. Cancer Res. 66 7 (2006) 3845-3851
92. Germano I.M., Fable J., Gultekin S.H., and Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J. Neurooncol. 65 3 (2003) 279-289
93. Goto T., Nishi T., Kobayashi O., Tamura T., Dev S.B., Takeshima H., Kochi M., Kuratsu J., Sakata T., and Ushio Y. Combination electro-gene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinomas in vivo. Mol. Ther. 10 5 (2004) 929-937
94. Greco O., and Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol. 187 1 (2001) 22-36
95. Greco O., Rossiter S., Kanthou C., Folkes L.K., Wardman P., Tozer G.M., and Dachs G.U. Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions. Mol. Cancer Ther. 1 2 (2001) 151-160
96. Green N.K., Youngs D.J., Neoptolemos J.P., Friedlos F., Knox R.J., Springer C.J., Anlezark G.M., Michael N.P., Melton R.G., Ford M.J., Young L.S., Kerr D.J., and Searle P.F. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 4 4 (1997) 229-238
97. Griffiths L., Binley K., Iqball S., Kan O., Maxwell P., Ratcliffe P., Lewis C., Harris A., Kingsman S., and Naylor S. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7 3 (2000) 255-262
98. Grove J.I., Lovering A.L., Guise C., Race P.R., Wrighton C.J., White S.A., Hyde E.I., and Searle P.F. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer Res. 63 17 (2003) 5532-5537
99. Gunther M., Waxman D.J., Wagner E., and Ogris M. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy. Cancer Gene Ther. 13 8 (2006) 771-779
100. Gunzburg W.H., and Salmons B. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer. Acta Biochim. Pol. 52 3 (2005) 601-607
101. Hamstra D.A., and Rehemtulla A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum. Gene Ther. 10 2 (1999) 235-248
102. Hamstra D.A., Rice D.J., Fahmy S., Ross B.D., and Rehemtulla A. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum. Gene Ther. 10 12 (1999) 1993-2003
103. Hanna N.N., Mauceri H.J., Wayne J.D., Hallahan D.E., Kufe D.W., and Weichselbaum R.R. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 57 19 (1997) 4205-4209
104. Hasenburg A., Tong X.W., Fischer D.C., Rojas-Martinez A., Nyberg-Hoffman C., Kaplan A.L., Kaufman R.H., Ramzy I., Aguilar-Cordova E., and Kieback D.G. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol. Oncol. 83 3 (2001) 549-554
105. Hasenburg A., Fischer D.C., Tong X.W., Rojas-Martinez A., Nyberg-Hoffman C., Orlowska-Volk M., Kohlberger P., Kaufman R.H., Ramzy I., Aguilar-Cordova E., and Kieback D.G. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Int. J. Gynecol. Cancer 12 1 (2002) 66-73
106. Hayashi K., Hayashi T., Sun H.D., and Takeda Y. Potentiation of ganciclovir toxicity in the herpes simplex virus thymidine kinase/ganciclovir administration system by ponicidin. Cancer Gene Ther. 7 1 (2000) 45-52
107. Hayashi K., Lee J.B., Maitani Y., Toyooka N., Nemoto H., and Hayashi T. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy. J. Gene Med. 8 8 (2006) 1056-1067
108. Hayden M.S., Linsley P.S., Wallace A.R., Marquardt H., and Kerr D.E. Cloning, overexpression, and purification of cytosine deaminase from Saccharomyces cerevisiae. Protein Expr. Purif. 12 2 (1998) 173-184
109. Hay M.P., Atwell G.J., Wilson W.R., Pullen S.M., and Denny W.A. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase. J. Med. Chem. 46 12 (2003) 2456-2466
110. Helsby N.A., Wheeler S.J., Pruijn F.B., Palmer B.D., Yang S., Denny W.A., and Wilson W.R. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem. Res. Toxicol. 16 4 (2003) 469-478
111. Helsby N.A., Ferry D.M., Patterson A.V., Pullen S.M., and Wilson W.R. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br. J. Cancer 90 5 (2004) 1084-1092
112. Howard B.D., Boenicke L., Schniewind B., Henne-Bruns D., and Kalthoff H. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir. Cancer Gene Ther. 7 6 (2000) 927-938
113. Huang Z., and Waxman D.J. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther. 8 6 (2001) 450-458
114. Huang Z., Raychowdhury M.K., and Waxman D.J. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Ther. 7 7 (2000) 1034-1042
115. Huber B.E., Richards C.A., and Krenitsky T.A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88 18 (1991) 8039-8043
116. Huber B.E., Austin E.A., Richards C.A., Davis S.T., and Good S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91 17 (1994) 8302-8306
117. Hughes B.W., Wells A.H., Bebok Z., Gadi V.K., Garver Jr. R.I., Parker W.B., and Sorscher E.J. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55 15 (1995) 3339-3345
118. Hughes B.W., King S.A., Allan P.W., Parker W.B., and Sorscher E.J. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J. Biol. Chem. 273 4 (1998) 2322-2328
119. Hwang K.S., Cho W.K., Yoo J., Yun H.J., Kim S., and Im D.S. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer 5 1 (2005) 51
120. Ilsley D.D., Lee S.H., Miller W.H., and Kuchta R.D. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry (Mosc). 34 8 (1995) 2504-2510
121. Immonen A., Vapalahti M., Tyynela K., Hurskainen H., Sandmair A., Vanninen R., Langford G., Murray N., and Yla-Herttuala S. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 10 5 (2004) 967-972
122. Ireton G.C., Black M.E., and Stoddard B.L. Crystallization and preliminary X-ray analysis of bacterial cytosine deaminase. Acta Crystallogr. D. Biol. Crystallogr. 57 Pt 11 (2001) 1643-1645
123. Jackson J.C., Duffy S.P., Hess K.R., and Mehl R.A. Improving nature's enzyme active site with genetically encoded unnatural amino acids. J. Am. Chem. Soc. 128 34 (2006) 11124-11127
124. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46 1-3 (2001) 149-168
125. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 5706 (2005) 58-62
126. Jiang Y., Han J., Yu C., Vass S.O., Searle P.F., Browne P., Knox R.J., and Hu L. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. J. Med. Chem. 49 14 (2006) 4333-4343
127. Jikai J., Shamis M., Huebener N., Schroeder U., Wrasidlo W., Wenkel J., Lange B., Gaedicke G., Shabat D., and Lode H.N. Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase. Cancer Lett. 197 1-2 (2003) 219-224
128. Jimenez T., Fox W.P., Naus C.C., Galipeau J., and Belliveau D.J. Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy. Cell Commun Adhes. 13 1-2 (2006) 79-92
129. Johannes L., and Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther. 12 18 (2005) 1360-1368
130. Johansson M., van Rompay A.R., Degreve B., Balzarini J., and Karlsson A. Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster. J. Biol. Chem. 274 34 (1999) 23814-23819
131. Jounaidi Y., and Waxman D.J. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 60 14 (2000) 3761-3769
132. Jounaidi Y., and Waxman D.J. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res. 61 11 (2001) 4437-4444
133. Jounaidi Y., and Waxman D.J. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res. 64 1 (2004) 292-303
134. Jounaidi Y., Hecht J.E., and Waxman D.J. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 58 19 (1998) 4391-4401
135. Kanai F., Kawakami T., Hamada H., Sadata A., Yoshida Y., Tanaka T., Ohashi M., Tateishi K., Shiratori Y., and Omata M. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res. 58 9 (1998) 1946-1951
136. Kaneda Y., and Tabata Y. Non-viral vectors for cancer therapy. Cancer Sci. 97 5 (2006) 348-354
137. Kan O., Griffiths L., Baban D., Iqball S., Uden M., Spearman H., Slingsby J., Price T., Esapa M., Kingsman S., Kingsman A., Slade A., and Naylor S. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther. 8 7 (2001) 473-482
138. Kan O., Kingsman S., and Naylor S. Cytochrome P450-based cancer gene therapy: current status. Expert Opin. Biol. Ther. 2 8 (2002) 857-868
139. Kanyama H., Tomita N., Yamano T., Miyoshi Y., Ohue M., Fujiwara Y., Sekimoto M., Sakita I., Tamaki Y., and Monden M. Enhancement of the anti-tumor effect of 5′-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells. Jpn. J. Cancer Res. 90 4 (1999) 454-459
140. Karle P., Muller P., Renz R., Jesnowski R., Saller R., von Rombs K., Nizze H., Liebe S., Gunzburg W.H., Salmons B., and Lohr M. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Adv. Exp. Med. Biol. 451 (1998) 97-106
141. Karle P., Renner M., Salmons B., and Gunzburg W.H. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther. 8 3 (2001) 220-230
142. Kawamura K., Tasaki K., Hamada H., Takenaga K., Sakiyama S., and Tagawa M. Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity. Cancer Gene Ther. 7 4 (2000) 637-643
143. Kawamura K., Bahar R., Namba H., Seimiya M., Takenaga K., Hamada H., Sakiyama S., and Tagawa M. Bystander effect in uracil phosphoribosyltransferase/5-fluorouracil-mediated suicide gene therapy is correlated with the level of intercellular communication. Int. J. Oncol. 18 1 (2001) 117-120
144. Kianmanesh A.R., Perrin H., Panis Y., Fabre M., Nagy H.J., Houssin D., and Klatzmann D. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum. Gene Ther. 8 15 (1997) 1807-1814
145. Kievit E., Bershad E., Ng E., Sethna P., Dev I., Lawrence T.S., and Rehemtulla A. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 59 7 (1999) 1417-1421
146. Kievit E., Nyati M.K., Ng E., Stegman L.D., Parsels J., Ross B.D., Rehemtulla A., and Lawrence T.S. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res. 60 23 (2000) 6649-6655
147. Kim I., Song X., Vig B.S., Mittal S., Shin H.C., Lorenzi P.J., and Amidon G.L. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol. Pharm. 1 2 (2004) 117-127
148. Klatzmann D., Cherin P., Bensimon G., Boyer O., Coutellier A., Charlotte F., Boccaccio C., Salzmann J.L., and Herson S. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum. Gene Ther. 9 17 (1998) 2585-2594
149. Klatzmann D., Valery C.A., Bensimon G., Marro B., Boyer O., Mokhtari K., Diquet B., Salzmann J.L., and Philippon J. A phase I/II study of herpes simplex virus type 1 thymidine kinase suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. 9 17 (1998) 2595-2604
150. Knox R.J., Friedlos F., Lydall D.A., and Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46 4 Pt 2 (1986) 1972-1979
151. Knox R.J., Boland M.P., Friedlos F., Coles B., Southan C., and Roberts J.J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 37 24 (1988) 4671-4677
152. Knox R.J., Friedlos F., Jarman M., and Roberts J.J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 37 24 (1988) 4661-4669
153. Knox R.J., Friedlos F., Sherwood R.F., Melton R.G., and Anlezark G.M. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 44 12 (1992) 2297-2301
154. Knox R.J., Burke P.J., Chen S., and Kerr D.J. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr. Pharm. Des. 9 26 (2003) 2091-2104
155. Kojima A., Hackett N.R., Ohwada A., and Crystal R.G. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J. Clin. Invest. 101 8 (1998) 1789-1796
156. Kokoris M.S., and Black M.E. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci. 11 9 (2002) 2267-2272
157. Kokoris M.S., Sabo P., Adman E.T., and Black M.E. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 6 8 (1999) 1415-1426
158. Kokoris M.S., Sabo P., and Black M.E. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res. 20 2A (2000) 959-963
159. Koyama F., Sawada H., Hirao T., Fujii H., Hamada H., and Nakano H. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther. 7 7 (2000) 1015-1022
160. Krohne T.U., Shankara S., Geissler M., Roberts B.L., Wands J.R., Blum H.E., and Mohr L. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 34 3 (2001) 511-518
161. Kubo H., Gardner T.A., Wada Y., Koeneman K.S., Gotoh A., Yang L., Kao C., Lim S.D., Amin M.B., Yang H., Black M.E., Matsubara S., Nakagawa M., Gillenwater J.Y., Zhau H.E., and Chung L.W. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. 14 3 (2003) 227-241
162. Kufe, D., Bast, R., Hait, W., Hong, W., Pollack, R., Weichselbaum, R., Holland, J., Frei, E., (Eds.), 2005. Cancer Medicine, vol. 7, Hamilton, Canada.
163. Kummar, S., Noronha, V., Chu, E., 2005. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (Eds.), Cancer Principles & Praxis of Oncology, Philadelphia, USA, pp. 362-364.
164. Kuriyama S., Masui K., Sakamoto T., Nakatani T., Kikukawa M., Tsujinoue H., Mitoro A., Yamazaki M., Yoshiji H., Fukui H., Ikenaka K., Mullen C.A., and Tsujii T. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res. 18 5A (1998) 3399-3406
165. Kuriyama S., Kikukawa M., Masui K., Okuda H., Nakatani T., Sakamoto T., Yoshiji H., Fukui H., Ikenaka K., Mullen C.A., and Tsujii T. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int. J. Cancer 81 4 (1999) 592-597
166. Lawrence T.S., Blackstock A.W., and McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin. Radiat. Oncol. 13 1 (2003) 13-21
167. Lee K.H., Piao H., Son B.R., Heo D.S., Kim N.K., and Kim S.T. Herpes simplex virus thymidine kinase and granulocyte macrophage colony-stimulating factor combination gene therapy in a murine CT26 cell colon cancer model. Cancer Gene Ther. 11 8 (2004) 570-576
168. Lee K.C., Hamstra D.A., Bullarayasamudram S., Bhojani M.S., Moffat B.A., Dornfeld K.J., Ross B.D., and Rehemtulla A. Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther. 13 2 (2006) 127-137
169. Lengler J., Omann M., Duvier D., Holzmuller H., Gregor W., Salmons B., Gunzburg W.H., and Renner M. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: implications for gene directed enzyme prodrug therapy. Biochem. Pharmacol. 72 7 (2006) 893-901
170. Liu S.C., Minton N.P., Giaccia A.J., and Brown J.M. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 9 4 (2002) 291-296
171. Lohr M., Muller P., Karle P., Stange J., Mitzner S., Jesnowski R., Nizze H., Nebe B., Liebe S., Salmons B., and Gunzburg W.H. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther. 5 8 (1998) 1070-1078
172. Lohr M., Bago Z.T., Bergmeister H., Ceijna M., Freund M., Gelbmann W., Gunzburg W.H., Jesnowski R., Hain J., Hauenstein K., Henninger W., Hoffmeyer A., Karle P., Kroger J.C., Kundt G., Liebe S., Losert U., Muller P., Probst A., Puschel K., Renner M., Renz R., Saller R., Salmons B., Walter I., et al. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. J. Mol. Med. 77 4 (1999) 393-398
173. Lohr M., Hoffmeyer A., Kroger J., Freund M., Hain J., Holle A., Karle P., Knofel W.T., Liebe S., Muller P., Nizze H., Renner M., Saller R.M., Wagner T., Hauenstein K., Gunzburg W.H., and Salmons B. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357 9268 (2001) 1591-1592
174. Lohr M., Hummel F., Faulmann G., Ringel J., Saller R., Hain J., Gunzburg W.H., and Salmons B. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. Cancer Chemother. Pharmacol. 49 Suppl 1 (2002) S21-S24
175. Manome Y., Wen P.Y., Dong Y., Tanaka T., Mitchell B.S., Kufe D.W., and Fine H.A. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat. Med. 2 5 (1996) 567-573
176. Marais R., Spooner R.A., Light Y., Martin J., and Springer C.J. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56 20 (1996) 4735-4742
177. Marais R., Spooner R.A., Stribbling S.M., Light Y., Martin J., and Springer C.J. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotechnol. 15 13 (1997) 1373-1377
178. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodefic. Rev. 3 1 (1991) 45-81
179. Martiniello-Wilks R., Garcia-Aragon J., Daja M.M., Russell P., Both G.W., Molloy P.L., Lockett L.J., and Russell P.J. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Ther. 9 11 (1998) 1617-1626
180. Mauger A.B., Burke P.J., Somani H.H., Friedlos F., and Knox R.J. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 37 21 (1994) 3452-3458
181. McCalla D.R., Kaiser C., and Green M.H. Genetics of nitrofurazone resistance in Escherichia coli. J. Bacteriol. 133 1 (1978) 6-10
182. McCarthy H.O., Yakkundi A., McErlane V., Hughes C.M., Keilty G., Murray M., Patterson L.H., Hirst D.G., McKeown S.R., and Robson T. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N. Cancer Gene Ther. 10 1 (2003) 40-48
183. McErlane V., Yakkundi A., McCarthy H.O., Hughes C.M., Patterson L.H., Hirst D.G., Robson T., and McKeown S.R. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J. Gene Med. 7 7 (2005) 851-859
184. McFadyen M.C., Melvin W.T., and Murray G.I. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol. Cancer Ther. 3 3 (2004) 363-371
185. McGeoch D.J., Dalrymple M.A., Davison A.J., Dolan A., Frame M.C., McNab D., Perry L.J., Scott J.E., and Taylor P. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J. Gen. Virol. 69 Pt 7 (1988) 1531-1574
186. McMasters R.A., Wilbert T.N., Jones K.E., Pitlyk K., Saylors R.L., Moyer M.P., Chambers T.C., and Drake R.R. Two-drug combinations that increase apoptosis and modulate bak and bcl-X(L) expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase. Cancer Gene Ther. 7 4 (2000) 563-573
187. McNeish I.A., Green N.K., Gilligan M.G., Ford M.J., Mautner V., Young L.S., Kerr D.J., and Searle P.F. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther. 5 8 (1998) 1061-1069
188. Mesnil M., and Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 60 15 (2000) 3989-3999
189. Metzl C., Mischek D., Salmons B., Gunzburg W.H., Renner M., and Portsmouth D. Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors. J. Virol. 80 14 (2006) 7070-7078
190. Miki K., Xu M., Gupta A., Ba Y., Tan Y., Al-Refaie W., Bouvet M., Makuuchi M., Moossa A.R., and Hoffman R.M. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res. 61 18 (2001) 6805-6810
191. Miles B.J., Shalev M., Aguilar-Cordova E., Timme T.L., Lee H.M., Yang G., Adler H.L., Kernen K., Pramudji C.K., Satoh T., Gdor Y., Ren C., Ayala G., Wheeler T.M., Butler E.B., Kadmon D., and Thompson T.C. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. 12 16 (2001) 1955-1967
192. Miller S.D., Mohiuddin I., Cao X.X., Ozvaran M.K., Daniel J.C., and Roy Smythe W. Gene therapy for sarcoma utilizing adenoviral transfer of the beta-glucuronidase and bax genes and an anthracyline prodrug. J. Surg. Res. 121 2 (2004) 153-158
193. Missol-Kolka E., Sochanik A., and Szala S. Combined therapy of B16(F10) murine melanoma using E. coli cytosine deaminase gene and murine interleukin-4 gene. Neoplasma 45 5 (1998) 305-311
194. Mohr L., Rainov N.G., Mohr U.G., and Wands J.R. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma. Cancer Gene Ther. 7 7 (2000) 1008-1014
195. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46 10 (1986) 5276-5281
196. Moriuchi S., Glorioso J.C., Maruno M., Izumoto S., Wolfe D., Huang S., Cohen J.B., and Yoshimine T. Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther. 12 5 (2005) 487-496
197. Mroz P.J., and Moolten F.L. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum. Gene Ther. 4 5 (1993) 589-595
198. Mullen C.A., Kilstrup M., and Blaese R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89 1 (1992) 33-37
199. Mullen C.A., Coale M.M., Lowe R., and Blaese R.M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 54 6 (1994) 1503-1506
200. Muller P., Jesnowski R., Karle P., Renz R., Saller R., Stein H., Puschel K., von Rombs K., Nizze H., Liebe S., Wagner T., Gunzburg W.H., Salmons B., and Lohr M. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. Ann. NY Acad. Sci. 880 (1999) 337-351
201. Munn L.L. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov. Today 8 9 (2003) 396-403
202. Murray G.I., Melvin W.T., and Burke M.D. Cytochrome P450 expression in tumours. J. Pathol. 176 3 (1995) 323-324
203. Nagata T., Nakamori M., Iwahashi M., and Yamaue H. Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5′-deoxy-5-fluorouridine in tumour cells in vitro and in vivo. Eur. J. Cancer 38 5 (2002) 712-717
204. Nanni P., De Giovanni C., Nicoletti G., Landuzzi L., Rossi I., Frabetti F., Giovarelli M., Forni G., Cavallo F., Di Carlo E., Musiani P., and Lollini P.L. The immune response elicited by mammary adenocarcinoma cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells. Hum. Gene Ther. 9 2 (1998) 217-224
205. Nemunaitis J., Cunningham C., Senzer N., Kuhn J., Cramm J., Litz C., Cavagnolo R., Cahill A., Clairmont C., and Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10 10 (2003) 737-744
206. Nicholas T.W., Read S.B., Burrows F.J., and Kruse C.A. Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol. Histopathol. 18 2 (2003) 495-507
207. Niculescu-Duvaz I., Scanlon I., Niculescu-Duvaz D., Friedlos F., Martin J., Marais R., and Springer C.J. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems. J. Med. Chem. 47 10 (2004) 2651-2658
208. Palmer D.H., Mautner V., Mirza D., Oliff S., Gerritsen W., van der Sijp J.R., Hubscher S., Reynolds G., Bonney S., Rajaratnam R., Hull D., Horne M., Ellis J., Mountain A., Hill S., Harris P.A., Searle P.F., Young L.S., James N.D., and Kerr D.J. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 22 9 (2004) 1546-1552
209. Parker W.B., King S.A., Allan P.W., Bennett Jr. L.L., Secrist III J.A., Montgomery J.A., Gilbert K.S., Waud W.R., Wells A.H., Gillespie G.Y., and Sorscher E.J. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther. 8 14 (1997) 1637-1644
210. Parker W.B., Allan P.W., Shaddix S.C., Rose L.M., Speegle H.F., Gillespie G.Y., and Bennett Jr. L.L. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. 55 10 (1998) 1673-1681
211. Parkinson G.N., Skelly J.V., and Neidle S. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J. Med. Chem. 43 20 (2000) 3624-3631
212. Patterson A.V., Williams K.J., Cowen R.L., Jaffar M., Telfer B.A., Saunders M., Airley R., Honess D., van der Kogel A.J., Wolf C.R., and Stratford I.J. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 9 14 (2002) 946-954
213. Pawlik T.M., Nakamura H., Mullen J.T., Kasuya H., Yoon S.S., Chandrasekhar S., Chiocca E.A., and Tanabe K.K. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 95 5 (2002) 1171-1181
214. Pederson L.C., Buchsbaum D.J., Vickers S.M., Kancharla S.R., Mayo M.S., Curiel D.T., and Stackhouse M.A. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 57 19 (1997) 4325-4332
215. Pereboeva L., and Curiel D.T. Cellular vehicles for cancer gene therapy: current status and future potential. BioDrugs 18 6 (2004) 361-385
216. Pierrefite-Carle V., Baque P., Gavelli A., Mala M., Chazal M., Gugenheim J., Bourgeon A., Milano G., Staccini P., and Rossi B. Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J. Natl. Cancer Inst. 91 23 (1999) 2014-2019
217. Prados M.D., McDermott M., Chang S.M., Wilson C.B., Fick J., Culver K.W., Van Gilder J., Keles G.E., Spence A., and Berger M. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J. Neurooncol. 65 3 (2003) 269-278
218. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11 17 (2000) 2389-2401
219. Rainov N.G., Dobberstein K.U., Sena-Esteves M., Herrlinger U., Kramm C.M., Philpot R.M., Hilton J., Chiocca E.A., and Breakefield X.O. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum. Gene Ther. 9 9 (1998) 1261-1273
220. Rainov N.G., Fels C., Droege J.W., Schafer C., Kramm C.M., and Chou T.C. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Ther. 8 9 (2001) 662-668
221. Richard C., Duivenvoorden W., Bourbeau D., Massie B., Roa W., Yau J., and Th'ng J. Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy. Cancer Gene Ther. (2006)
222. Riddick D.S., Lee C., Ramji S., Chinje E.C., Cowen R.L., Williams K.J., Patterson A.V., Stratford I.J., Morrow C.S., Townsend A.J., Jounaidi Y., Chen C.S., Su T., Lu H., Schwartz P.S., and Waxman D.J. Cancer chemotherapy and drug metabolism. Drug Metab. Dispos. 33 8 (2005) 1083-1096
223. Riley R.J., and Workman P. DT-diaphorase and cancer chemotherapy. Biochem. Pharmacol. 43 8 (1992) 1657-1669
224. Robe P.A., Princen F., Martin D., Malgrange B., Stevenaert A., Moonen G., Gielen J., Merville M., and Bours V. Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3′,5′-cyclic monophosphate, alpha-glycyrrhetinic acid, and cytosine arabinoside. Biochem. Pharmacol. 60 2 (2000) 241-249
225. Robe P.A., Jolois O., N'Guyen M., Princen F., Malgrange B., Merville M.P., and Bours V. Modulation of the HSV-TK/ganciclovir bystander effect by n-butyrate in glioblastoma: correlation with gap-junction intercellular communication. Int. J. Oncol. 25 1 (2004) 187-192
226. Roberts J.J., Friedlos F., and Knox R.J. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem. Biophys. Res. Commun. 140 3 (1986) 1073-1078
227. Robson T., Worthington J., McKeown S.R., and Hirst D.G. Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity. Technol. Cancer Res. Treat. 4 4 (2005) 343-361
228. Rodrigues M.L., Carter P., Wirth C., Mullins S., Lee A., and Blackburn B.K. Systhesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem. Biol. 2 4 (1995) 223-227
229. Rooseboom M., Commandeur J.N., and Vermeulen N.P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 56 1 (2004) 53-102
230. Rosenberg E., Hawkins W., Holmes M., Amir C., Schmidt-Ullrich R.K., Lin P.S., and Valerie K. Radiosensitization of human glioma cells in vitro and in vivo with acyclovir and mutant HSV-TK75 expressed from adenovirus. Int. J. Radiat. Oncol. Biol. Phys. 52 3 (2002) 831-836
231. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., and Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 129 1-2 (2000) 77-97
232. Roy V., Qiao J., de Campos-Lima P., and Caruso M. Direct evidence for the absence of intercellular trafficking of VP22 fused to GFP or to the herpes simplex virus thymidine kinase. Gene Ther. 12 2 (2005) 169-176
233. Salmons B., Lohr M., and Gunzburg W.H. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial. J. Gastroenterol. 38 Suppl (2003) 1578-1584
234. Sanda A., Zhu C., Johansson M., and Karlsson A. Bystander effects of nucleoside analogs phosphorylated in the cytosol or mitochondria. Biochem. Biophys. Res. Commun. 287 5 (2001) 1163-1166
235. Sastry S.S., and Jayaraman R. Nitrofurantoin-resistant mutants of Escherichia coli: isolation and mapping. Mol. Gen. Genet. 196 2 (1984) 379-380
236. Satoh T., Teh B.S., Timme T.L., Mai W.Y., Gdor Y., Kusaka N., Fujita T., Pramudji C.K., Vlachaki M.T., Ayala G., Wheeler T., Amato R., Miles B.J., Kadmon D., Butler E.B., and Thompson T.C. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 59 2 (2004) 562-571
237. Saukkonen K., and Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin. Biol. Ther. 4 5 (2004) 683-696
238. Savage P., Cowburn P., Clemens D., Hurley T., Laguda B., Martin-Duque P., Vassaux G., and Lemoine N.R. Suicide gene therapy: conversion of ethanol to acetaldehyde mediated by human beta 2 alcohol dehydrogenase. Cancer Gene Ther. 11 12 (2004) 774-781
239. Schepelmann S., Hallenbeck P., Ogilvie L.M., Hedley D., Friedlos F., Martin J., Scanlon I., Hay C., Hawkins L.K., Marais R., and Springer C.J. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res. 65 12 (2005) 5003-5008
240. Schwartz P.S., and Waxman D.J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol. 60 6 (2001) 1268-1279
241. Schwartz P.S., Chen C.S., and Waxman D.J. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Cancer Res. 62 23 (2002) 6928-6937
242. Scripture C.D., and Figg W.D. Drug interactions in cancer therapy. Nat. Rev. Cancer 6 7 (2006) 546-558
243. Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol. Ther. 4 5 (2005) 512-517
244. Sharma S.K., Bagshawe K.D., and Begent R.H. Advances in antibody-directed enzyme prodrug therapy. Curr. Opin. Investig. Drugs 6 6 (2005) 611-615
245. Sherwood R.F., Melton R.G., Alwan S.M., and Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur. J. Biochem. 148 3 (1985) 447-453
246. Shiau A.L., Yang H.M., Wu P., and Wu C.L. Provision of positive and negative selections in retroviral vectors containing the cytosine deaminase gene. Gene Ther. 5 11 (1998) 1571-1574
247. Silamkoti A.V., Allan P.W., Hassan A.E., Fowler A.T., Sorscher E.J., Parker W.B., and Secrist III J.A. Synthesis and biological activity of 2-fluoro adenine and 6-methyl purine nucleoside analogs as prodrugs for suicide gene therapy of cancer. Nucleo. Nucleo. Nucl. Acids 24 5-7 (2005) 881-885
248. Simonova M., Wall A., Weissleder R., and Bogdanov Jr. A. Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res. 60 23 (2000) 6656-6662
249. Sladek N.E. Metabolism of oxazaphosphorines. Pharmacol. Ther. 37 3 (1988) 301-355
250. Sladek N.E. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr. Pharm. Des. 5 8 (1999) 607-625
251. Smitt P.S., Driesse M., Wolbers J., Kros M., and Avezaat C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol. Ther. 7 6 (2003) 851-858
252. Sorscher E.J., Peng S., Bebok Z., Allan P.W., Bennett Jr. L.L., and Parker W.B. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1 4 (1994) 233-238
253. Spooner R.A., Friedlos F., Maycroft K., Stribbling S.M., Roussel J., Brueggen J., Stolz B., O'Reilly T., Wood J., Matter A., Marais R., and Springer C.J. A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. Br. J. Cancer 88 10 (2003) 1622-1630
254. Springer C.J., Antoniw P., Bagshawe K.D., Searle F., Bisset G.M., and Jarman M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33 2 (1990) 677-681
255. Stackhouse M.A., Pederson L.C., Grizzle W.E., Curiel D.T., Gebert J., Haack K., Vickers S.M., Mayo M.S., and Buchsbaum D.J. Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther. 7 12 (2000) 1019-1026
256. Stefani A.L., Barzon L., Castagliuolo I., Guido M., Pacenti M., Parolin C., Farinati F., and Palu G. Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinoma. J. Hepatol. 42 5 (2005) 728-735
257. Sterman D.H., Recio A., Vachani A., Sun J., Cheung L., DeLong P., Amin K.M., Litzky L.A., Wilson J.M., Kaiser L.R., and Albelda S.M. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin. Cancer Res. 11 20 (2005) 7444-7453
258. Stribbling S.M., Friedlos F., Martin J., Davies L., Spooner R.A., Marais R., and Springer C.J. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum. Gene Ther. 11 2 (2000) 285-292
259. Tai C.K., Wang W.J., Chen T.C., and Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol. Ther. 12 5 (2005) 842-851
260. Tasciotti E., and Giacca M. Fusion of the human immunodeficiency virus type 1 tat protein transduction domain to thymidine kinase increases bystander effect and induces enhanced tumor killing in vivo. Hum. Gene Ther. 16 12 (2005) 1389-13403
261. Teh B.S., Ayala G., Aguilar L., Mai W.Y., Timme T.L., Vlachaki M.T., Miles B., Kadmon D., Wheeler T., Caillouet J., Davis M., Carpenter L.S., Lu H.H., Chiu J.K., Woo S.Y., Thompson T., Aguilar-Cordova E., and Butler E.B. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int. J. Radiat. Oncol. Biol. Phys. 58 5 (2004) 1520-1529
262. Theys J., Landuyt W., Nuyts S., Van Mellaert L., van Oosterom A., Lambin P., and Anne J. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 8 4 (2001) 294-297
263. Thompson J. Protocol #0207-544: a phase study to evaluate the safety and pharmacokinetics of Pro-1, a liposome-encapsulated thymidine kinase gene formulation, in patients with stage IV metastatic melanoma. Hum. Gene Ther. 14 3 (2003) 310-312
264. Tomicic M.T., Bey E., Wutzler P., Thust R., and Kaina B. Comparative analysis of DNA breakage, chromosomal aberrations and apoptosis induced by the anti-herpes purine nucleoside analogues aciclovir, ganciclovir and penciclovir. Mutat. Res. 505 1-2 (2002) 1-11
265. Touraine R.L., Ishii-Morita H., Ramsey W.J., and Blaese R.M. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 5 12 (1998) 1705-1711
266. Townsend D.M., Findlay V.J., Fazilev F., Ogle M., Fraser J., Saavedra J.E., Ji X., Keefer L.K., and Tew K.D. A glutathione-S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol. Pharmacol. 69 2 (2006) 501-508
267. Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 28 1 (1989) 113-121
268. Tupper J., Tozer G.M., and Dachs G.U. Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol. Br. J. Cancer 90 9 (2004) 1858-1862
269. Tychopoulos M., Corcos L., Genne P., Beaune P., and de Waziers I. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein. Cancer Gene Ther. 12 5 (2005) 497-508
270. Udawatte C., and Ripps H. The spread of apoptosis through gap-junctional channels in BHK cells transfected with Cx32. Apoptosis 10 5 (2005) 1019-1029
271. Valerie K., Brust D., Farnsworth J., Amir C., Taher M.M., Hershey C., and Feden J. Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther. 7 6 (2000) 879-884
272. Valerie K., Hawkins W., Farnsworth J., Schmidt-Ullrich R., Lin P.S., Amir C., and Feden J. Substantially improved in vivo radiosensitization of rat glioma with mutant HSV-TK and acyclovir. Cancer Gene Ther. 8 1 (2001) 3-8
273. van Dillen I.J., Mulder N.H., Vaalburg W., de Vries E.F., and Hospers G.A. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr. Gene Ther. 2 3 (2002) 307-322
274. Vile R.G., Castleden S., Marshall J., Camplejohn R., Upton C., and Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71 2 (1997) 267-274
275. Vrionis F.D., Wu J.K., Qi P., Waltzman M., Cherington V., and Spray D.C. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther. 4 6 (1997) 577-585
276. Wahlfors T., Hakkarainen T., Janne J., Alhonen L., and Wahlfors J. In vivo enhancement of herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy with polyamine biosynthesis inhibition. Int. J. Cancer 118 11 (2006) 2907-2910
277. Wang Z.H., Samuels S., Gama Sosa M.A., and Kolodny E.H. 5-Fluorocytosine-mediated apoptosis and DNA damage in glioma cells engineered to express cytosine deaminase and their enhancement with interferon. J. Neurooncol. 36 3 (1998) 219-229
278. Wardman P. Indole-3-acetic acids and horseradish peroxidase: a new prodrug/enzyme combination for targeted cancer therapy. Curr. Pharm. Des. 8 15 (2002) 1363-1374
279. Weedon S.J., Green N.K., McNeish I.A., Gilligan M.G., Mautner V., Wrighton C.J., Mountain A., Young L.S., Kerr D.J., and Searle P.F. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int. J. Cancer 86 6 (2000) 848-854
280. Wei K., and Huber B.E. Cytosine deaminase gene as a positive selection marker. J. Biol. Chem. 271 7 (1996) 3812-3816
281. Wei M.X., Tamiya T., Chase M., Boviatsis E.J., Chang T.K., Kowall N.W., Hochberg F.H., Waxman D.J., Breakefield X.O., and Chiocca E.A. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5 8 (1994) 969-978
282. Wei M.X., Tamiya T., Rhee R.J., Breakefield X.O., and Chiocca E.A. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin. Cancer Res. 1 10 (1995) 1171-1177
283. Wiewrodt R., Amin K., Kiefer M., Jovanovic V.P., Kapoor V., Force S., Chang M., Lanuti M., Black M.E., Kaiser L.R., and Albelda S.M. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther. 10 5 (2003) 353-364
284. Wildner O., Blaese R.M., and Morris J.C. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. Hum. Gene Ther. 10 16 (1999) 2679-2687
285. Willmon C.L., Krabbenhoft E., and Black M.E. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Ther. 13 17 (2006) 1309-1312
286. Wybranietz W.A., Gross C.D., Phelan A., O'Hare P., Spiegel M., Graepler F., Bitzer M., Stahler P., Gregor M., and Lauer U.M. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther. 8 21 (2001) 1654-1664
287. Yakkundi A., McErlane V., Murray M., McCarthy H.O., Ward C., Hughes C.M., Patterson L.H., Hirst D.G., McKeown S.R., and Robson T. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer Gene Ther. 13 6 (2006) 598-605
288. Yamamoto S., Suzuki S., Hoshino A., Akimoto M., and Shimada T. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther. 4 2 (1997) 91-96
289. Yamamoto N., Gupta A., Xu M., Miki K., Tsujimoto Y., Tsuchiya H., Tomita K., Moossa A.R., and Hoffman R.M. Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cells. Cancer Gene Ther. 10 6 (2003) 445-450
290. Yamamoto S., Yamano T., Tanaka M., Hoon D.S., Takao S., Morishita R., Aikou T., and Kaneda Y. A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther. 10 3 (2003) 179-186
291. Yamasaki H., Enomoto K., Fitzgerald D.J., Mesnil M., Katoh F., and Hollstein M. Role of intercellular communication in the control of critical gene expression during multistage carcinogenesis. IARC Sci. Publ. 92 (1988) 57-75
292. Yamasaki H., Krutovskikh V., Mesnil M., Tanaka T., Zaidan-Dagli M.L., and Omori Y. Role of connexin (gap junction) genes in cell growth control and carcinogenesis. CR Acad. Sci. III 322 2-3 (1999) 151-159
293. Yamasaki, H., Omori, Y., Krutovskikh, V., Zhu, W., Mironov, N., Yamakage, K., Mesnil, M., 1999b. Connexins in tumour suppression and cancer therapy. Novartis Found. Symp. 219 241-54; discussion 254-60.
294. Yi C., Huang Y., Guo Z.Y., and Wang S.R. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol. Sin. 26 5 (2005) 629-634
295. Yu L.J., Matias J., Scudiero D.A., Hite K.M., Monks A., Sausville E.A., and Waxman D.J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos. 29 3 (2001) 304-312
296. Zhang L.X., Acevedo P., Guo H., and Bertram J.S. Upregulation of gap junctional communication and connexin43 gene expression by carotenoids in human dermal fibroblasts but not in human keratinocytes. Mol. Carcinog. 12 1 (1995) 50-58
297. Zhang J.H., Wan M.X., Pan B.R., and Yu B. Cytotoxicity of HSVtk and hrTNF-alpha fusion genes with IRES in treatment of gastric cancer. Cancer Lett. 235 2 (2006) 191-201
298. Zhang Q., Chen G., Peng L., Wang X., Yang Y., Liu C., Shi W., Su C., Wu H., Liu X., Wu M., and Qian Q. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin. Cancer Res. 12 21 (2006) 6523-6531
299. Zheng X., Johansson M., and Karlsson A. Nucleoside analog cytotoxicity and bystander cell killing of cancer cells expressing Drosophila melanogaster deoxyribonucleoside kinase in the nucleus or cytosol. Biochem. Biophys. Res. Commun. 289 1 (2001) 229-233
300. Zimmerman T.P., Gersten N.B., Ross A.F., and Miech R.P. Adenine as substrate for purine nucleoside phosphorylase. Can. J. Biochem. 49 9 (1971) 1050-1054